These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 33707082)

  • 1. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
    Fleseriu M; Castinetti F
    Pituitary; 2016 Dec; 19(6):643-653. PubMed ID: 27600150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
    Engelhardt D; Weber MM
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Cushing's syndrome with osilodrostat: practical applications of recent studies with case examples.
    Fleseriu M; Biller BMK
    Pituitary; 2022 Dec; 25(6):795-809. PubMed ID: 36002784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenally Directed Medical Therapies for Cushing Syndrome.
    Tritos NA
    J Clin Endocrinol Metab; 2021 Jan; 106(1):16-25. PubMed ID: 33118025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
    Feelders RA; Hofland LJ; de Herder WW
    Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
    Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
    Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
    Braun LT; Reincke M
    Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101376. PubMed ID: 32063487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osilodrostat (Isturisa) for Cushing's disease.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):21-23. PubMed ID: 33647005
    [No Abstract]   [Full Text] [Related]  

  • 15. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
    Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
    Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in the medical treatment of Cushing's syndrome.
    Schteingart DE
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
    Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.